Repeated 5-aminolevulinic acid mediated sonodynamic therapy using magnetic resonance guided focused ultrasound in rat brain tumour models
Abstract Sonodynamic therapy is an emerging therapeutic approach against brain tumours. However, the treatment scheme and ultrasound parameters have yet to be explored for clinical translation. Our study aimed to optimize ultrasound parameters for sonodynamic therapy (SDT) with 5-ALA as a sonosensit...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-025-85314-6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1841544680973533184 |
---|---|
author | Sheng-Kai Wu Chia-Lin Tsai Aisha Mir Stuart L. Marcus Kullervo Hynynen |
author_facet | Sheng-Kai Wu Chia-Lin Tsai Aisha Mir Stuart L. Marcus Kullervo Hynynen |
author_sort | Sheng-Kai Wu |
collection | DOAJ |
description | Abstract Sonodynamic therapy is an emerging therapeutic approach against brain tumours. However, the treatment scheme and ultrasound parameters have yet to be explored for clinical translation. Our study aimed to optimize ultrasound parameters for sonodynamic therapy (SDT) with 5-ALA as a sonosensitizing agent and to evaluate its therapeutic outcome on the rodent 9L gliosarcoma and the human U87 glioblastoma models. We stereotactically implanted brain tumour cells in rats and monitored tumour volume via MRI. SDT was conducted weekly using a 60 mg/kg dose of 5-ALA, injected intravenously 6 h before sonication. We used a driving frequency of 580 kHz with 0.75 MPa and evaluated the effect of different burst lengths to optimize ultrasound parameters. We also tested SDT against advanced-stage brain tumours to verify its efficacy further. Our results showed that a longer burst length could improve therapeutic outcomes. Tumour growth inhibition was established only in the first three weeks with 10 ms and 50 ms burst length sonication, but 86 ms burst length greatly improved the survival outcome. Therefore, the therapeutic efficacy is proportionate to the burst length and, thus, the total delivered energy. Repeated SDT using multiple targets to cover the entire tumour volume with optimal ultrasound parameters can achieve significant anti-tumour effects in both 9L and U87 models. Lastly, our results on late-stage tumour treatments showed that SDT can still provide prolonged survival. These promising findings demonstrate that repeated SDT using transcranial-focused ultrasound together with 5-ALA can optimize anti-tumour effects and even lead to complete clearance of the tumours. This weekly treatment with pulsed ultrasound sonication strategy is practical for future clinical translation. |
format | Article |
id | doaj-art-8f180c43245b4d16bf675ea3b0e0dc80 |
institution | Kabale University |
issn | 2045-2322 |
language | English |
publishDate | 2025-01-01 |
publisher | Nature Portfolio |
record_format | Article |
series | Scientific Reports |
spelling | doaj-art-8f180c43245b4d16bf675ea3b0e0dc802025-01-12T12:22:07ZengNature PortfolioScientific Reports2045-23222025-01-0115111010.1038/s41598-025-85314-6Repeated 5-aminolevulinic acid mediated sonodynamic therapy using magnetic resonance guided focused ultrasound in rat brain tumour modelsSheng-Kai Wu0Chia-Lin Tsai1Aisha Mir2Stuart L. Marcus3Kullervo Hynynen4Physical Sciences Platform, Sunnybrook Research InstitutePhysical Sciences Platform, Sunnybrook Research InstitutePhysical Sciences Platform, Sunnybrook Research InstituteSonALAsense IncPhysical Sciences Platform, Sunnybrook Research InstituteAbstract Sonodynamic therapy is an emerging therapeutic approach against brain tumours. However, the treatment scheme and ultrasound parameters have yet to be explored for clinical translation. Our study aimed to optimize ultrasound parameters for sonodynamic therapy (SDT) with 5-ALA as a sonosensitizing agent and to evaluate its therapeutic outcome on the rodent 9L gliosarcoma and the human U87 glioblastoma models. We stereotactically implanted brain tumour cells in rats and monitored tumour volume via MRI. SDT was conducted weekly using a 60 mg/kg dose of 5-ALA, injected intravenously 6 h before sonication. We used a driving frequency of 580 kHz with 0.75 MPa and evaluated the effect of different burst lengths to optimize ultrasound parameters. We also tested SDT against advanced-stage brain tumours to verify its efficacy further. Our results showed that a longer burst length could improve therapeutic outcomes. Tumour growth inhibition was established only in the first three weeks with 10 ms and 50 ms burst length sonication, but 86 ms burst length greatly improved the survival outcome. Therefore, the therapeutic efficacy is proportionate to the burst length and, thus, the total delivered energy. Repeated SDT using multiple targets to cover the entire tumour volume with optimal ultrasound parameters can achieve significant anti-tumour effects in both 9L and U87 models. Lastly, our results on late-stage tumour treatments showed that SDT can still provide prolonged survival. These promising findings demonstrate that repeated SDT using transcranial-focused ultrasound together with 5-ALA can optimize anti-tumour effects and even lead to complete clearance of the tumours. This weekly treatment with pulsed ultrasound sonication strategy is practical for future clinical translation.https://doi.org/10.1038/s41598-025-85314-6Sonodynamic therapy5-Aminolevulinic acidBrain tumourMR-guided focused ultrasoundBurst length |
spellingShingle | Sheng-Kai Wu Chia-Lin Tsai Aisha Mir Stuart L. Marcus Kullervo Hynynen Repeated 5-aminolevulinic acid mediated sonodynamic therapy using magnetic resonance guided focused ultrasound in rat brain tumour models Scientific Reports Sonodynamic therapy 5-Aminolevulinic acid Brain tumour MR-guided focused ultrasound Burst length |
title | Repeated 5-aminolevulinic acid mediated sonodynamic therapy using magnetic resonance guided focused ultrasound in rat brain tumour models |
title_full | Repeated 5-aminolevulinic acid mediated sonodynamic therapy using magnetic resonance guided focused ultrasound in rat brain tumour models |
title_fullStr | Repeated 5-aminolevulinic acid mediated sonodynamic therapy using magnetic resonance guided focused ultrasound in rat brain tumour models |
title_full_unstemmed | Repeated 5-aminolevulinic acid mediated sonodynamic therapy using magnetic resonance guided focused ultrasound in rat brain tumour models |
title_short | Repeated 5-aminolevulinic acid mediated sonodynamic therapy using magnetic resonance guided focused ultrasound in rat brain tumour models |
title_sort | repeated 5 aminolevulinic acid mediated sonodynamic therapy using magnetic resonance guided focused ultrasound in rat brain tumour models |
topic | Sonodynamic therapy 5-Aminolevulinic acid Brain tumour MR-guided focused ultrasound Burst length |
url | https://doi.org/10.1038/s41598-025-85314-6 |
work_keys_str_mv | AT shengkaiwu repeated5aminolevulinicacidmediatedsonodynamictherapyusingmagneticresonanceguidedfocusedultrasoundinratbraintumourmodels AT chialintsai repeated5aminolevulinicacidmediatedsonodynamictherapyusingmagneticresonanceguidedfocusedultrasoundinratbraintumourmodels AT aishamir repeated5aminolevulinicacidmediatedsonodynamictherapyusingmagneticresonanceguidedfocusedultrasoundinratbraintumourmodels AT stuartlmarcus repeated5aminolevulinicacidmediatedsonodynamictherapyusingmagneticresonanceguidedfocusedultrasoundinratbraintumourmodels AT kullervohynynen repeated5aminolevulinicacidmediatedsonodynamictherapyusingmagneticresonanceguidedfocusedultrasoundinratbraintumourmodels |